Monopar offers a highly asymmetric orphan-drug opportunity: a cash-rich, pre-revenue biotech whose valuation now hinges on ALXN1840’s FDA path and commercial launch in Wilson disease.
Overview
Monopar Therapeutics is a pre-revenue, clinical-stage biotech that transformed its profile by licensing ALXN1840, a late-stage Wilson disease therapy, from Alexion/AstraZeneca. The asset offers once-daily dosing, compelling copper mobilization, and lower neurological worsening versus standard chelators. With no product revenue today, Monopar is funded by a strong $137.5 million cash and investment balance following a major 2025 financing. Its upside depends on FDA approval, commercialization of ALXN1840, potential international partnerships, and longer-term optionality from radiopharmaceutical oncology assets.